By Barbara Obstoj-Cardwell. Editor
Last week’s notable announcements included Swiss pharma giant Roche saying it has regenerated a previously dropped compound, tominersen - licensed from Ionis Pharmaceuticals, to develop it for Huntington’s disease. Belgium’s biggest pharma firm UCB announced a takeover bid worth up to $1.9 billion for USA-based Zogenix and its epilepsy drug Fintepla. Biotech firm Altos Labs came out of stealth with some $3 billion in financing and luring GlaxoSmithKline’s research chief Hal Barron to be its chief executive, along with several notables to its team. On the research front, Alnylam Pharmaceuticals presented new data supporting its investigational drug vutrisiran in transthyretin amyloidosis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze